

# Stamford Pharmaceuticals Inc Announces Clinical Collaboration with Roche to Evaluate SP-002 in Combination with vismodegib in Patients with basal cell carcinoma

April 1st, 2020 07:00 AM Eastern Daylight Time

Greenwich, CT.--([BUSINESS WIRE](#))—[Stamford Pharmaceuticals, Inc.](#), Stamford pharmaceuticals a clinical stage immunology and inflammation focused company developing novel combination therapies for cancers, today announced a clinical collaboration with Roche (SIX:RO, ROG) to explore SP-002 (formerly ASN-002/TG1042), Stamford’s adenoviral vector immunotherapy, in combination with Roche’s vismodegib (Erivedge®), a Hedgehog Pathway inhibitor approved for the treatment of adult patients presenting with locally advanced and metastatic basal cell carcinoma. The combination study will be conducted in patients with multiple basal cell carcinomas (BCCs).

“This collaboration is an opportunity to create a new treatment paradigm for patients with multiple BCCs.” said Clement Leong, PhD., Stamford Pharmaceutical’s Chief Executive Officer. “We believe that SP-002 when combined with vismodegib has potential to enhance the response rate<sup>1</sup> of BCC lesions directly injected with SP-002 but can also confer responses in distant non-injected BCCs. This would represent a major advancement for the management of patients with multiple BCCs who currently have to endure the morbidity that arises from many surgical procedures.”

SP-002 is an adenoviral-5 vector-based immunotherapy encoding the gene for human Interferon- $\gamma$ . It will be evaluated in combination with a reduced duration of vismodegib treatment. It is expected that the combination will alter the tumor microenvironment to support more potent and durable anti-tumor responses, while using a shorter duration of vismodegib treatment to optimize tolerability. Stamford Pharmaceuticals plans to initiate an open-label, multicenter Phase 2a clinical trial of SP-002 administered as an intra-lesional injection to patients who have multiple basal cell carcinomas in both the basal cell nevus and sporadic BCC populations. The primary objective of the study is to evaluate the efficacy, safety and tolerability of SP-002 in combination with vismodegib in both target (lesions injected with SP-002) and non-target (non-injected) lesions. Stamford Pharmaceuticals will be the sponsor of the study and Roche will provide vismodegib and clinical and scientific support for the study.

---

<sup>1</sup> Based on a composite endpoint of Complete Response (clinical assessment) and Histological Clearance

## **About Stamford Pharmaceuticals Inc.**

Stamford pharmaceuticals is clinical stage immunology and inflammation focused company developing rational combination therapies that aim to improve patient lives. Cancers are complex dynamic and adaptive diseases where the tumor micro-environment comprises many different cell types, matrix proteins and secreted molecules. These elements form a highly redundant regulatory network that enables continued tumor survival, adaptation and progression even in the face of potent treatments. There is clear evidence that single-target drugs do not provide durable outcomes for many patients. We believe that taking a network multi-target approach offers a better opportunity to improving response rates and durability by maximizing synergistic efficacy while reducing off-target toxicities.

## **Contacts**

Stamford Pharmaceuticals Inc.  
Info@stamfordPharmaceuticals.com  
[www.stamfordpharmaceuticals.com](http://www.stamfordpharmaceuticals.com)